WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563412

CAS#: 81921-45-1

Description: 2MeSAMP is a P2Y(12) antagonist. It acts by inhibiting platelet activation through P2Y(12)/G(i)-dependent mechanism.

Chemical Structure

CAS# 81921-45-1

Theoretical Analysis

MedKoo Cat#: 563412
Name: 2MeSAMP
CAS#: 81921-45-1
Chemical Formula: C11H14N5Na2O7PS
Exact Mass:
Molecular Weight: 437.27
Elemental Analysis: C, 30.21; H, 3.23; N, 16.02; Na, 10.52; O, 25.61; P, 7.08; S, 7.33

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: 2MeSAMP; 2-MeS-AMP bis-sodium; 2MeSAMP bis-sodium; 2 MeS AMP bis-sodium;

IUPAC/Chemical Name: 2-(Methylthio)-5'-adenylic acid disodium salt


InChi Code: InChI=1S/C11H16N5O7PS.2Na/c1-25-11-14-8(12)5-9(15-11)16(3-13-5)10-7(18)6(17)4(23-10)2-22-24(19,20)21;;/h3-4,6-7,10,17-18H,2H2,1H3,(H2,12,14,15)(H2,19,20,21);;/q;2*+1/p-2/t4-,6-,7-,10-;;/m1../s1

SMILES Code: O=P([O-])(OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C(N=C(SC)N=C32)N)O1)O)O)[O-].[Na+].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 437.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Tourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat M. Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2644-50. doi: 10.1161/ATVBAHA.114.304249. Epub 2014 Oct 2. PubMed PMID: 25278289; PubMed Central PMCID: PMC4239175.

2: Li R, Diamond SL. Detection of platelet sensitivity to inhibitors of COX-1, P2Y₁, and P2Y₁₂ using a whole blood microfluidic flow assay. Thromb Res. 2014 Feb;133(2):203-10. doi: 10.1016/j.thromres.2013.10.043. Epub 2013 Nov 6. PubMed PMID: 24365044; PubMed Central PMCID: PMC3932538.

3: Liñán-Rico A, Wunderlich JE, Grants IS, Frankel WL, Xue J, Williams KC, Harzman AE, Enneking JT, Cooke HJ, Christofi FL. Purinergic autocrine regulation of mechanosensitivity and serotonin release in a human EC model: ATP-gated P2X3 channels in EC are downregulated in ulcerative colitis. Inflamm Bowel Dis. 2013 Oct;19(11):2366-79. doi: 10.1097/MIB.0b013e31829ecf4d. PubMed PMID: 23917247; PubMed Central PMCID: PMC4037929.

4: Herfindal L, Nygaard G, Kopperud R, Krakstad C, Døskeland SO, Selheim F. Off-target effect of the Epac agonist 8-pCPT-2'-O-Me-cAMP on P2Y12 receptors in blood platelets. Biochem Biophys Res Commun. 2013 Aug 9;437(4):603-8. doi: 10.1016/j.bbrc.2013.07.007. Epub 2013 Jul 12. PubMed PMID: 23850619.

5: Arachiche A, de la Fuente M, Nieman MT. Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets. PLoS One. 2013;8(2):e55740. doi: 10.1371/journal.pone.0055740. Epub 2013 Feb 6. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/0956857d-ecf5-4fb7-a834-131915a38a6a. PubMed PMID: 23405206; PubMed Central PMCID: PMC3566007.

6: Xiang B, Zhang G, Ren H, Sunkara M, Morris AJ, Gartner TK, Smyth SS, Li Z. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism. PLoS One. 2012;7(12):e51037. doi: 10.1371/journal.pone.0051037. Epub 2012 Dec 6. PubMed PMID: 23236426; PubMed Central PMCID: PMC3516503.

7: Vavra V, Bhattacharya A, Zemkova H. Facilitation of glutamate and GABA release by P2X receptor activation in supraoptic neurons from freshly isolated rat brain slices. Neuroscience. 2011 Aug 11;188:1-12. doi: 10.1016/j.neuroscience.2011.04.067. Epub 2011 May 7. PubMed PMID: 21575687.

8: McIlvain HB, Ma L, Ludwig B, Manners MT, Martone RL, Dunlop J, Kaftan EJ, Kennedy JD, Whiteside GT. Purinergic receptor-mediated morphological changes in microglia are transient and independent from inflammatory cytokine release. Eur J Pharmacol. 2010 Sep 25;643(2-3):202-10. doi: 10.1016/j.ejphar.2010.06.046. Epub 2010 Jul 13. PubMed PMID: 20621081.

9: Srinivasan S, Mir F, Huang JS, Khasawneh FT, Lam SC, Le Breton GC. The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J Biol Chem. 2009 Jun 12;284(24):16108-17. doi: 10.1074/jbc.M809780200. Epub 2009 Apr 3. PubMed PMID: 19346255; PubMed Central PMCID: PMC2713557.

10: Shenkman B, Einav Y, Salomon O, Varon D, Savion N. Testing agonist-induced platelet aggregation by the Impact-R [Cone and plate(let) analyzer (CPA)]. Platelets. 2008 Sep;19(6):440-6. doi: 10.1080/09537100802082256. Erratum in: Platelets. 2008 Dec;19(8):641. PubMed PMID: 18925512.

11: Carrasquero LM, Delicado EG, Jiménez AI, Pérez-Sen R, Miras-Portugal MT. Cerebellar astrocytes co-express several ADP receptors. Presence of functional P2Y(13)-like receptors. Purinergic Signal. 2005 Jun;1(2):153-9. doi: 10.1007/s11302-005-6211-3. Epub 2005 Mar 7. PubMed PMID: 18404500; PubMed Central PMCID: PMC2096534.

12: Seo DR, Kim SY, Kim KY, Lee HG, Moon JH, Lee JS, Lee SH, Kim SU, Lee YB. Cross talk between P2 purinergic receptors modulates extracellular ATP-mediated interleukin-10 production in rat microglial cells. Exp Mol Med. 2008 Feb 29;40(1):19-26. PubMed PMID: 18305394; PubMed Central PMCID: PMC2679320.

13: Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):315-22. PubMed PMID: 16845449.

14: Hardy AR, Hill DJ, Poole AW. Evidence that the purinergic receptor P2Y12 potentiates platelet shape change by a Rho kinase-dependent mechanism. Platelets. 2005 Nov;16(7):415-29. PubMed PMID: 16236603.

15: Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Matsushime H, Furuichi K. Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9. PubMed PMID: 11502873.

16: Jantzen HM, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds EE, Conley PB. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb Haemost. 1999 Jan;81(1):111-7. PubMed PMID: 10348701.